Up 200% in a year! Why is this ASX healthcare stock rocketing today?

This stock just can't stop rising. What is it this time?

One ASX healthcare stock is catching the eye on Thursday with a particularly strong gain.

That stock is Imricor Medical Systems Inc (ASX: IMR), which is a leading developer of innovative MRI-compatible medical devices that can be used to carry out MRI guided cardiac catheter ablation procedures.

At the time of writing, its shares are up 11% to $1.57.

This means that Imricor Medical Systems shares are now up a massive 200% since this time last year.

A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

Why is this ASX healthcare stock rocketing?

Investors have responded positively to news that the company has received firm commitments for a placement to new and existing institutional and sophisticated investors to raise $70 million.

According to the release, the ASX healthcare stock is raising the funds through the issue of 49,645,392 new CHESS Depositary Interests (CDIs) at an issue price of $1.41 per new CDI.

This was in line with where its shares were trading before their trading halt, which appears to indicate that demand was very strong for this placement.

Why is it raising funds?

The release notes that the funds raised from the placement, together with its existing cash balance, will be used to support the company's growth strategy.

This includes growing its installed base and expanding indications in Europe, expanding commercial operations into key markets, such as the USA and Middle East, and funding ongoing research, development, and regulatory efforts.

The ASX healthcare stock expects to have cash reserves of approximately $87.3 million (US$55.0 million) after costs following completion of the placement. Management believes that this leaves it well-positioned for continued growth and operational success in 2025 and beyond.

Imricor Medical Systems' chair and CEO, Steve Wedan, was pleased with the success of the placement. He commented:

2025 is a year full of meaningful catalysts and groundbreaking milestones. With this raise, we have a balance sheet that is bolstered to not only achieve these milestones, but to also drive well past them. We are in a great position to deliver on the promise of real-time MRI guidance for medical interventions, and we are more energised than ever to make it happen.

Index inclusion

It has been a big month for the ASX healthcare stock.

As well as this good news, the company was given a boost recently by S&P Dow Jones Indices.

It revealed that the company's shares will be added to the All Ordinaries index on 24 March following the quarterly rebalance.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »